Last reviewed · How we verify
Tryparsone (tryparsamide)
Tryparsone (generic name: tryparsamide) is a drug. It is currently in unknown development.
Tryparsone works by inhibiting the enzyme dihydrofolate reductase, which is essential for the survival of the trypanosome parasite.
Tryparsone is a small molecule. It is used to treat African trypanosomiasis, also known as sleeping sickness, according to ClinicalTrials.gov.
At a glance
| Generic name | tryparsamide |
|---|---|
| Therapeutic area | Other |
| Phase | unknown |
Mechanism of action
Think of it like a key that fits into a lock. The lock is the enzyme dihydrofolate reductase, and the key is Tryparsone. When Tryparsone fits into the lock, it prevents the enzyme from working properly, which ultimately kills the parasite.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tryparsone CI brief — competitive landscape report
- Tryparsone updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Tryparsone
What is Tryparsone?
How does Tryparsone work?
What is the generic name of Tryparsone?
What development phase is Tryparsone in?
Related
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing